KR20220034176A - 치아의 재생 치료를 위한 usag-1을 표적 분자로 한 중화 항체 - Google Patents

치아의 재생 치료를 위한 usag-1을 표적 분자로 한 중화 항체 Download PDF

Info

Publication number
KR20220034176A
KR20220034176A KR1020227004179A KR20227004179A KR20220034176A KR 20220034176 A KR20220034176 A KR 20220034176A KR 1020227004179 A KR1020227004179 A KR 1020227004179A KR 20227004179 A KR20227004179 A KR 20227004179A KR 20220034176 A KR20220034176 A KR 20220034176A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227004179A
Other languages
English (en)
Korean (ko)
Inventor
가츠 다카하시
마나부 스가이
요시히토 도키타
준이치 다카기
에미코 미하라
Original Assignee
고쿠리츠 다이가쿠 호진 교토 다이가쿠
고쿠리츠다이가쿠호징 후쿠이다이가쿠
고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠 다이가쿠 호진 교토 다이가쿠, 고쿠리츠다이가쿠호징 후쿠이다이가쿠, 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 filed Critical 고쿠리츠 다이가쿠 호진 교토 다이가쿠
Publication of KR20220034176A publication Critical patent/KR20220034176A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
KR1020227004179A 2019-07-12 2020-07-10 치아의 재생 치료를 위한 usag-1을 표적 분자로 한 중화 항체 Pending KR20220034176A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2019-130153 2019-07-12
JP2019130153 2019-07-12
JP2020080723 2020-04-30
JPJP-P-2020-080723 2020-04-30
PCT/JP2020/027127 WO2021010346A1 (ja) 2019-07-12 2020-07-10 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体

Publications (1)

Publication Number Publication Date
KR20220034176A true KR20220034176A (ko) 2022-03-17

Family

ID=74209883

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227004179A Pending KR20220034176A (ko) 2019-07-12 2020-07-10 치아의 재생 치료를 위한 usag-1을 표적 분자로 한 중화 항체

Country Status (6)

Country Link
US (1) US20220259298A1 (https=)
EP (1) EP4000633A4 (https=)
JP (2) JP7572668B2 (https=)
KR (1) KR20220034176A (https=)
CN (2) CN114364694B (https=)
WO (1) WO2021010346A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240043841A1 (en) * 2020-02-21 2024-02-08 Kyoto University Medicine Containing USAG-1-Targeting RNA Molecule for Tooth Regeneration Therapy
JPWO2023148894A1 (https=) * 2022-02-03 2023-08-10
CN116425870A (zh) * 2023-05-24 2023-07-14 陕西师范大学 一种抗新型冠状病毒n蛋白单克隆抗体31a8及其产品和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8176798A (en) * 1997-06-30 1999-01-19 Genetics Institute Inc. Secreted proteins
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
CN1618807A (zh) * 2003-11-21 2005-05-25 上海人类基因组研究中心 分泌蛋白及其编码序列和用途
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
EP3345607B1 (en) * 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
AU2008330125B2 (en) * 2007-11-21 2012-11-22 Amgen Inc. Wise binding antibodies and epitopes
GB0911060D0 (en) * 2009-06-26 2009-08-12 Ge Healthcare Uk Ltd Methods for predicting the toxicity of a chemical
US20120288507A1 (en) * 2009-12-18 2012-11-15 Amgen Inc. Wise binding agents and epitopes
JP6107654B2 (ja) * 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
US11485787B2 (en) * 2014-02-05 2022-11-01 Dana-Farber Cancer Institute, Inc. Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
CN115636880A (zh) * 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
US12084495B2 (en) * 2016-08-03 2024-09-10 Nextcure, Inc. Compositions and methods for modulating LAIR signal transduction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nakao, Nat Methods, 2007
Ohazama, J Denr Res, 2004

Also Published As

Publication number Publication date
WO2021010346A1 (ja) 2021-01-21
CN118307669A (zh) 2024-07-09
US20220259298A1 (en) 2022-08-18
JP7572668B2 (ja) 2024-10-24
JP2021176829A (ja) 2021-11-11
CN114364694B (zh) 2024-05-10
EP4000633A1 (en) 2022-05-25
EP4000633A4 (en) 2024-02-21
JP2025004094A (ja) 2025-01-14
CN114364694A (zh) 2022-04-15

Similar Documents

Publication Publication Date Title
JP7044399B2 (ja) タウ免疫療法
CN107847595B (zh) 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
CN109415432B (zh) Tau免疫疗法
JP7627469B2 (ja) 抗ｔｉｇｉｔ抗体、その調製方法と応用
JP6483086B2 (ja) 骨形成不全症の処置方法
CN113286817A (zh) Dll3结合蛋白及使用方法
JP2025004094A (ja) 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
BR112020017296A2 (pt) Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
US9908933B2 (en) Antibody therapy for amyloid beta disease
CN110494449B (zh) Alt-803与抗cd38抗体组合用于癌症治疗
TW202216773A (zh) 識別分選蛋白(sortilin)的抗體
JP2024079697A (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体２のアンタゴニスト及びアゴニスト
CN115698060A (zh) 环肽
US20250136674A1 (en) Usag-1 molecule-targeting neutralizing antibody for tooth regeneration treatment
HK40107636A (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
HK40073445A (en) Neutralizing antibody for tooth regeneration treatment targeting usag-1 molecule
HK40073445B (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
HK40114319A (zh) 靶向usag-1分子的用於牙齿再生治疗的中和抗体
WO2023247312A1 (en) Anti-transthyretin (ttr) binding proteins and uses thereof
JP2006206524A (ja) 可溶化インターロイキン１８レセプター及び医薬組成物並びに疾患の診断方法
NZ712353B2 (en) Methods for treating osteogenesis imperfecta

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D13 Search requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D13-SRH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000